Anticoagulation in Autoimmune Rheumatic Diseases

Citation:
Ragab, G., M. T. Hegazy, V. Codullo, M. Mattar, and J. Avouac, "Anticoagulation in Autoimmune Rheumatic Diseases", Precision Anticoagulation Medicine: A Practical Guide, Cham, Springer International Publishing, pp. 159 - 179, 2020.

Abstract:

Autoimmune rheumatic diseases as a group are characterized by common features such as multisystem involvement, polypharmacy, and the presence of comorbidities. Recent large epidemiological studies shed light on their role as risk factors for thromboembolic complications. The pathogenic factors are now better understood. The proposed mechanisms for this increased risk include increased hypercoagulability, lack of inhibitors, and other factors. The group of vasculitis which includes Behçet’s disease, giant cell vasculitis, Takayasu’s arteritis, and ANCA-associated vasculitis deserves special attention. However other diseases such as systemic lupus erythematosus, Sjögren syndrome, scleroderma, rheumatoid and psoriatic arthritis, myositis, and sarcoidosis are also associated with significantly increased risk of thrombosis.

Notes:

n/a

Related External Link